Georgetown University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Georgetown University sits in the top decile of US sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count).

227 total trials 34 currently recruiting 130 completed early-phase tilt top decile by trial count

Georgetown University: 227 sponsored US clinical trials, 34 recruiting.

Georgetown University sponsors 227 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 130 completed. 27 of these trials are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 5 trials.

Top-decile sponsor footprint

Georgetown University ranks in the top decile of sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 26/100

130 of 174 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

227 total, page 5 of 5

COMPLETED NA

Study on Effective Mydriasis in Premature Infants

NCT01054027

TERMINATED Phase 1

Vascular Sealant Study

NCT00618358

COMPLETED NA

Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants

NCT00459238

COMPLETED Phase 3

Decreasing Rates of Illness in Kids (DRINK)

NCT00356382

TERMINATED Phase 2

Placebo Controlled Trial of Bosentan in Scleroderma Patients

NCT00377455

COMPLETED Phase 3

Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions

NCT00262899

COMPLETED

Measurement of Hormone Levels in Patients Receiving 17-HPC for Preterm Delivery

NCT00457886

COMPLETED Phase 3

Chinese Women and Mammography Screening

NCT01261520

COMPLETED NA

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

NCT00287898

COMPLETED

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949

COMPLETED

Urban Environmental Exposures and Childhood Cancer

NCT00505141

COMPLETED Phase 3

Prostate Cancer Screening: Fostering Informed Decisions

NCT00196807

COMPLETED NA

Internet and Telephone Counseling for Smoking Cessation

NCT00282009

COMPLETED NA

Cognitive Therapy to Improve Word Finding

NCT00494520

COMPLETED Phase 2

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

NCT00073073

COMPLETED NA

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

NCT01324245

COMPLETED Phase 3

Treatment Decision Making in Early-Stage Prostate Cancer

NCT00196781

TERMINATED Phase 2

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

NCT00088829

COMPLETED Phase 1

Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer

NCT00020748

TERMINATED

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

NCT00898937

COMPLETED NA

Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis

NCT00004495

COMPLETED Phase 2

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

NCT00003125

COMPLETED Phase 1

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer

NCT00003297

COMPLETED Phase 2

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

NCT00003035

COMPLETED Phase 1

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

NCT00004030

COMPLETED NA

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

NCT00905073

COMPLETED Phase 1

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

NCT00091741

← Previous Page 5 of 5

Phase Distribution

PhaseTrial count
Phase 1 43
Phase 2 55
Phase 3 16
Phase 4 11

What is open in the Georgetown University pipeline

34 recruiting of 227 indexed (15% open); 130 completed (57%).

Phase mix: 27 late (III/IV) vs 98 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Georgetown University: open-pipeline peers nationwide

Peers matched on 227 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250 5%10%15%20% Total trials Recruiting share Georgetown UniversityUniversity of IowaUniversity Hospitals Cleveland Medical CenterBrown UniversityNational Eye Institute (NEI)Arizona State University59th Medical WingAlliance Foundation TrialsHoag Memorial Hospital Presbyterian
Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 227 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Georgetown University page

227 registered trials is a research-attention snapshot, not an endorsement of Georgetown University or any single study.

  • 34 of Georgetown University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Georgetown University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Georgetown University pipeline card: 227 registered trials from official public datasets.Report a data error.